[{"id":"d51630cc-a526-4c45-ba50-82d026376318","acronym":"U31402-A-J101","url":"https://clinicaltrials.gov/study/NCT02980341","created_at":"2021-01-17T17:33:44.191Z","updated_at":"2025-02-25T16:05:30.233Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT02980341 - U31402-A-J101","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" HER-2 • ERBB3","pipe":" | ","alterations":" HR positive • HER-2 negative • HER-2 expression • ERBB3 positive","tags":["HER-2 • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HER-2 expression • ERBB3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Completed","enrollment":" Enrollment 182","initiation":"Initiation: 11/28/2016","start_date":" 11/28/2016","primary_txt":" Primary completion: 08/16/2021","primary_completion_date":" 08/16/2021","study_txt":" Completion: 09/07/2023","study_completion_date":" 09/07/2023","last_update_posted":"2024-10-30"}]